#United States #Liquid Biopsy #Henderson #VolitionRx #Capture-Seq™

VolitionRx's Revolutionary Capture-Seq™ Liquid Biopsy

Introduction
In a landmark achievement for cancer diagnostics, VolitionRx Limited (NYSE AMERICAN: VNRX) has published its first peer-reviewed paper detailing the cutting-edge Capture-Seq™ technology. This novel liquid biopsy method is set to redefine early cancer detection and offers a promising avenue for improvements in clinical outcomes for patients worldwide.

Overview of Capture-Seq™ Technology
Capture-Seq™ is a newly developed liquid biopsy technology designed to isolate and analyze circulating tumor-derived DNA (ctDNA) with unprecedented accuracy. Unlike conventional liquid biopsy methods that often yield mixed results due to contamination from non-cancerous cell DNA, Capture-Seq™ successfully achieves a remarkable purity rate of over 99% in the samples it processes. The recent publication outlines the methodology behind this innovation, revealing advancements that pave the way for more effective cancer diagnostics.

Scientific Validation
The key to Capture-Seq™’s success lies in its ability to meticulously extract ctDNA from blood plasma while eradicating the background noise of healthy cellular DNA. The published research, titled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq," provides insights into the underlying chemical differences between cancer-derived and healthy DNA. This pioneering work is anticipated to address longstanding challenges in the field of liquid biopsies.

Dr. Jake Micallef, the Chief Scientific Officer at VolitionRx, shared his enthusiasm, stating that their findings could represent one of the most significant breakthroughs in cancer testing in recent years. With a new two-step process that incorporates both physical enrichment and bioinformatic refinement, the Capture-Seq™ method enables clinicians to focus precisely on the ctDNA, minimizing the possibility of false positives and enhancing early-stage cancer detection rates.

Market Potential
VolitionRx is currently engaged in discussions with global leaders in diagnostics to advance the commercialization of Capture-Seq™ technology. According to the company, the Total Addressable Market (TAM) for this approach in Multi-Cancer Early Detection (MCED) and Minimum Residual Disease (MRD) detection is projected to surpass $36 billion annually. This figure reflects a broad spectrum of potential applications across various cancer types, illustrating the significant commercial opportunity that lies ahead.

Clinical Implications
Initial validation cohorts indicate high sensitivity in cancer detection, revealing that Capture-Seq™ achieved over 95% accuracy for early-stage cancers in recent studies. Such success could resolve crucial healthcare challenges, facilitating earlier interventions that could dramatically improve patient outcomes. As it stands, the approach is not just a new procedure, but a potential game-changer in the realm of personalized medicine.

Looking Ahead
Excitement around Capture-Seq™ is building, both within the scientific community and the medical industry. Future research will involve larger sample sets and collaborations with key opinion leaders in oncology to further refine and validate the technology. VolitionRx’s commitment to innovation and their proactive approach toward R&D projects could position them at the forefront of oncology diagnostics.

Conclusion
VolitionRx's publication marks a milestone not only for the company but also for the diagnosis and early detection of cancers. As Capture-Seq™ progresses through clinical trials and into commercial application, the potential impact on patient care and cancer management is profound. With ongoing studies and collaborations on the horizon, VolitionRx stands poised to lead the charge in revolutionizing cancer diagnostics, bringing hope to countless individuals facing this formidable disease.